echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Development Pharmaceuticals PD-L1/TGF-β dual target antibody obtained clinical trial license in China

    Development Pharmaceuticals PD-L1/TGF-β dual target antibody obtained clinical trial license in China

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Suzhou, October 21, 2021/PRNewswire/ - On October 21, 2021, Kaifeng Pharmaceutical Co.


    GT90008 is a dual-target antibody against PD-L1 and TGF-βR2, which can simultaneously inhibit the high activity of PD-L1 and TGF-βR2, and has the potential to become a best-in-class drug


    Dr.


    About Kaixing Pharmaceutical

    Founded in 2009, Kapport Pharmaceuticals focuses on the development and industrialization of potential "best-in-class" and "first-in-class" innovative drugs, and is committed to becoming a leader in the research, development and commercialization of innovative therapies


    Source: Kaifeng Pharmaceutical

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.